These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31916129)

  • 1. The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.
    Al-Hakeim HK; Almulla AF; Maes M
    Neurotox Res; 2020 Mar; 37(3):753-771. PubMed ID: 31916129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.
    Al-Dujaili AH; Mousa RF; Al-Hakeim HK; Maes M
    Schizophr Bull; 2021 Mar; 47(2):530-541. PubMed ID: 32971537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions.
    Sirivichayakul S; Kanchanatawan B; Thika S; Carvalho AF; Maes M
    CNS Neurol Disord Drug Targets; 2019; 18(2):124-140. PubMed ID: 30451122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis.
    Kanchanatawan B; Sriswasdi S; Thika S; Stoyanov D; Sirivichayakul S; Carvalho AF; Geffard M; Maes M
    J Eval Clin Pract; 2018 Aug; 24(4):879-891. PubMed ID: 29790237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia.
    Al-Hakeim HK; Almulla AF; Al-Dujaili AH; Maes M
    Curr Top Med Chem; 2020; 20(9):747-758. PubMed ID: 31994463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In schizophrenia, psychomotor retardation is associated with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde.
    Maes M; Sirivichayakul S; Kanchanatawan B; Carvalho AF
    World J Biol Psychiatry; 2020 Jun; 21(5):383-401. PubMed ID: 32031479
    [No Abstract]   [Full Text] [Related]  

  • 7. Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia.
    Kanchanatawan B; Sriswasdi S; Maes M
    Metab Brain Dis; 2019 Feb; 34(1):267-282. PubMed ID: 30467771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities in chemokine levels in schizophrenia and their clinical correlates.
    Hong S; Lee EE; Martin AS; Soontornniyomkij B; Soontornniyomkij V; Achim CL; Reuter C; Irwin MR; Eyler LT; Jeste DV
    Schizophr Res; 2017 Mar; 181():63-69. PubMed ID: 27650194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.
    Maes M; Sirivichayakul S; Matsumoto AK; Maes A; Michelin AP; de Oliveira Semeão L; de Lima Pedrão JV; Moreira EG; Barbosa DS; Geffard M; Carvalho AF; Kanchanatawan B
    Mol Neurobiol; 2020 May; 57(5):2333-2345. PubMed ID: 32040834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowered serum cesium levels in schizophrenia: association with immune-inflammatory biomarkers and cognitive impairments.
    Almulla AF; Moustafa SR; Al-Dujaili AH; Al-Hakeim HK; Maes M
    Braz J Psychiatry; 2021; 43(2):131-137. PubMed ID: 32556004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel schizophrenia subgroup "major neurocognitive psychosis" is validated as a distinct class through the analysis of immune-linked neurotoxicity biomarkers and neurocognitive deficits.
    Popov P; Chen C; Al-Hakeim HK; Al-Musawi AF; Al-Dujaili AH; Stoyanov D; Maes M
    Brain Behav Immun Health; 2024 Oct; 40():100842. PubMed ID: 39263314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia.
    Almulla AF; Al-Hakeim HK; Maes M
    CNS Spectr; 2021 Aug; 26(4):368-377. PubMed ID: 32431263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major neurocognitive psychosis: a novel schizophrenia endophenotype class that is based on machine learning and resembles Kraepelin's and Bleuler's conceptions.
    Maes M
    Acta Neuropsychiatr; 2023 Jun; 35(3):123-137. PubMed ID: 36373497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.
    Mousa RF; Al-Hakeim HK; Alhaideri A; Maes M
    Metab Brain Dis; 2021 Jan; 36(1):169-183. PubMed ID: 32965599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning.
    Kanchanatawan B; Sriswasdi S; Thika S; Sirivichayakul S; Carvalho AF; Geffard M; Kubera M; Maes M
    Metab Brain Dis; 2018 Aug; 33(4):1053-1067. PubMed ID: 29527624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: a Nomothetic Network Psychiatry Approach.
    Maes M; Sirivichayakul S; Matsumoto AK; Michelin AP; de Oliveira Semeão L; de Lima Pedrão JV; Moreira EG; Barbosa DS; Carvalho AF; Solmi M; Kanchanatawan B
    Mol Neurobiol; 2020 Nov; 57(11):4578-4597. PubMed ID: 32754898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways.
    Almulla AF; Al-Hakeim HK; Abed MS; Carvalho AF; Maes M
    Schizophr Res; 2020 Aug; 222():342-353. PubMed ID: 32467068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related to Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Learning Study.
    Kanchanatawan B; Thika S; Sirivichayakul S; Carvalho AF; Geffard M; Maes M
    Neurotox Res; 2018 Apr; 33(3):641-655. PubMed ID: 29380275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Schizophrenia, Increased Plasma IgM/IgA Responses to Gut Commensal Bacteria Are Associated with Negative Symptoms, Neurocognitive Impairments, and the Deficit Phenotype.
    Maes M; Kanchanatawan B; Sirivichayakul S; Carvalho AF
    Neurotox Res; 2019 Apr; 35(3):684-698. PubMed ID: 30552634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.